eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Molnlycke Health Care

Two Omega Drive, Irlam, Manchester, M44 5BJ , UK
Telephone: +44 (0)161 777 2600
Fax: +44 (0)161 777 2601
WWW: http://www.molnlycke.com
Medical Information Direct Line: +44 (0)161 777 2628
Medical Information e-mail: ukmedical.information@molnlycke.com
Customer Care direct line: +44 (0)161 777 2600
Medical Information Fax: +44 (0)161 621 2045

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 26/09/2006
SPC Hibicet Hospital Concentrate


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Hibicet Hospital Concentrate.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Chlorhexidine gluconate 1.5% w/v (incorporated as Chlorhexidine Gluconate Solution Ph.Eur. 7.5% v/v); cetrimide 15% w/v (incorporated as strong cetrimide solution Ph.Eur.)


Go to top of the page
3. PHARMACEUTICAL FORM

Liquid.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Hibicet Hospital Concentrate is an antimicrobial preparation with cleansing properties for general antiseptic purposes.


Go to top of the page
4.2 Posology and method of administration

For external use only. Dilute as follows:

Method of Preparation

Dilution

Use

10ml made up to 1 litre with water

1 in 100 (1%) aqueous

Cleansing/antiseptic treatment of wounds and burns *

Swabbing in obstetrics, gynaecology and urology.

Cleansing/disinfectant soak for used metal instruments.

Clean instrument disinfection where no means of sterilisation is available (30 minutes immersion)**

Cleansing/disinfection of equipment, furniture and fittings in the vicinity of the patient.

Storage of clinical thermometers and sterile instruments.

35ml made up to 1 litre with water

1 in 30 (approx) aqueous

Cleansing/antiseptic treatment of wounds and burns where greater cleansing/antisepsis is required*

Cleansing/disinfectant soak for soiled instruments.

35ml with 200ml water made up to 1 litre with 95% alcohol

1 in 30 (approx) in 70% alcohol

Rapid skin antisepsis before operation and other invasive procedures.

Disinfection of clean instruments and equipment (2 minutes immersion)**

Disinfection of clinical thermometers.

* sterilise the dilution by autoclaving at 115º– 116ºC for 30 minutes or 121º– 123ºC for 15 minutes

** endoscopes should not be placed in solution of Hibicet

Children and elderly patients: there are no special dosage recommendations for either elderly patients or children. The normal adult dose is appropriate unless otherwise recommended by the physician.


Go to top of the page
4.3 Contraindications

Hibicet preparations are contraindicated for patients who have previously shown a hypersensitivity reaction to either chlorhexidine or cetrimide. However, such reactions are extremely rare.


Go to top of the page
4.4 Special warnings and precautions for use

For external use only. Dilute before use. Avoid contact with the brain, meninges and ears. Not for injection. Do not use in body cavities or as an enema.

The concentrated solution is irritant to eyes and mucous membranes. Keep all solutions out of the eyes. If solutions do come into contact with eyes, wash out promptly and thoroughly with water. If concentrated cetrimide solutions come into contact with the skin, rinse promptly and thoroughly with water.

Prolonged skin contact with alcoholic solutions should be avoided. Allow to dry before proceeding.

Solutions applied to wounds, burns or broken skin should be sterilised according to BP recommendations.

Syringes and needles which have been immersed in Hibicet solutions should be thoroughly rinsed in sterile water or saline before use.

Hibicet solutions may affect glass cement and therefore are not suitable for the disinfection of endoscopes.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

See section 6.2.


Go to top of the page
4.6 Pregnancy and lactation

There is no evidence of any adverse effects on the foetus arising from the use of Hibicet Hospital Concentrate during pregnancy. Therefore no special precautions are recommended.


Go to top of the page
4.7 Effects on ability to drive and use machines

None have been reported or are known.


Go to top of the page
4.8 Undesirable effects

Irritative skin reactions can occasionally occur and rare hypersensitivity to cetrimide preparations, usually developing after repeated application, has been reported.

There have been rare reports of severe burn-like reactions to concentrate cetrimide solutions. Should such a reaction occur treat as a chemical burn.

Generalised allergic reactions to chlorhexidine have also been reported but are extremely rare.

In all these cases, stop application of the product.


Go to top of the page
4.9 Overdose

This has not been reported.

Accidental oral or rectal administration:

If the product is swallowed give large quantities of milk, raw egg, gelatin or mild soap. Avoid vomiting or lavage if it is believed that a concentrated solution has been ingested. Central paralysis cannot be countered by curare antagonists or CNS stimulants but sympathomimetic drugs have been given.

Mechanically assisted ventilation with oxygen may be necessary. Persistent convulsions may be controlled with cautious doses of diazepam or a short-acting barbiturate. Do not give alcohol in any form.

Accidental intravenous infusion:

Massive haemolysis can occur which will require blood transfusion.

Accidental intra-uterine administration:

Introduction into the uterus can lead to haemolysis and pulmonary embolism.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Hibicet Hospital Concentrate is a topical antiseptic for external use only and is not intended to be administered orally or parenterally. The active agents, chlorhexidine gluconate and cetrimide are strongly cationic, binding to skin, mucosa and exposed tissues, this percutaneous absorption is poor. There are, as a consequence, no general pharmacological studies available on the effects of Hibicet Hospital Concentrate or other topically administered chlorhexidine/cetrimide formulations.

If chlorhexidine is systemically absorbed there is no evidence of metabolic cleavage of the drug, however, animal studies suggest that systemically absorbed cetrimide may be metabolised to some extent.

Both active agents have a broad spectrum of antimicrobial activity and are bacteriostatic at low concentrations whilst at higher concentrations their activity is rapidly bactericidal. They are both active against dermatophytic fungi (including the yeast C. albicans) and enveloped viruses such as HIV.


Go to top of the page
5.2 Pharmacokinetic properties

Percutaneous absorption of the active agents in Hibicet Hospital Concentrate is poor. Studies in animals using 14C-labelled cetrimide have shown that even after oral dosing only small amounts were found in the blood plasmas and approximately 2% was excreted in the bile during the first 12 hours after treatment: only small amounts of radioactivity were found in the liver, kidneys, spleen, heart, lungs and skeletal muscle and tissue radioactivity declined rapidly.

Similarly, attempts to detect percutaneous absorption of chlorhexidine gluconate in man have shown that, if it occurs at all, the level is exceedingly small and insignificant – the limit of detection used being of the order of 0.005mg/litre.

Furthermore, it is very unlikely that the pharmacokinetic properties of either chlorhexidine gluconate or cetrimide will be altered significantly in special situations, such as hepatic failure, renal failure, treatment of children, the elderly, in pregnancy or nursing mothers.


Go to top of the page
5.3 Preclinical safety data

Chlorhexidine and cetrimide are drugs on which extensive clinical experience has been obtained. All relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Benzyl benzoate; industrial methylated spirit; D-gluconolactone; isopropyl alcohol; liquid deodorizer; purified water; sodium hydroxide; Sunset Yellow FCF (E110); terpineol


Go to top of the page
6.2 Incompatibilities

Hypochlorite bleaches may cause brown stains to develop in fabrics which have previously been in contact with preparations containing chlorhexidine. Chlorhexidine and cetrimide are incompatible with soap and other anionic agents.


Go to top of the page
6.3 Shelf life

4 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 30ºC


Go to top of the page
6.5 Nature and contents of container

White HDPE bottle with a white tamper evident HDPE screw cap (5 litres).


Go to top of the page
6.6 Special precautions for disposal and other handling

Dilute for use.

Dilute with tap water of an acceptable bacteriological standard or alcohol (ethanol, industrial methylated spirits or isopropanol). Add diluent slowly to prevent excessive foaming.

As a precaution against bacterial contamination, aqueous stock solutions should contain at least 4% v/v of isopropanol or 7% v/v of ethanol which may be denatured (ie industrial methylated spirit).

Hibicet solutions used for instrument storage should contain 0.4% w/v sodium nitrite to inhibit metal corrosion. Such solutions must be changed every 7 days. Prolonged immersion of rubber appliances in Hibicet solutions is undesirable.

As cork may protect certain gram-negative organisms from the action of antiseptics, Hibicet solutions must be stored in bottles with glass, plastic or rubber closures.

See also section 4.2 and 4.4


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Regent Medical Overseas Limited, Two Omega Drive, River Bend Technology Centre, Irlam, Manchester, M44 5BJ, United Kingdom.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 21855/0001.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

30th December 2004.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

December 2004.



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/18856/SPC/


Active Ingredients/Generics

 
   cetrimide
   chlorhexidine gluconate